lupus.bmj

LSO-090 A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a potent dual BAFF ...

Background Povetacicept (ALPN-303) is an Fc fusion protein of a variant, engineered TACI domain, which mediates significantly more potent inhibitory activity than WT TACI-Fc or BAFF- or APRIL-specific ...
Lupus Science & Medicine

Age-related patterns of organ damage impact on health-related quality of life in SLE

Objective To characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in ...
Lupus Science & Medicine

Association between disease duration and comorbidity burden in systemic lupus erythematosus: a multicentre study from Pakistan

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...
lupus.bmj

2021 DORIS definition of remission in SLE: final recommendations from an international task force

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been ...
lupus.bmj

11 Managing haematologic manifestations in SLE

Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
lupus.bmj

Table of contents

22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...
lupus.bmj

12 Family planning and pregnancy in SLE

Case 1: A 35-year-old female with SLE and planning IVF pregnancy In October 2024 a 35-year-old female with systemic lupus erythematosus (SLE) was reviewed for planning of in vitro fertilization (IVF) ...
lupus.bmj

Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura

Background SLE complicated with thrombotic thrombocytopenic purpura (SLE-TTP) is a rare but potentially fatal condition. Current studies regarding SLE-TTP are limited to case reports and literature ...
lupus.bmj

Lupus nephritis serum induces changes in gene expression in human glomerular endothelial cells, which is modulated by L-sepiapterin: implications for redox-mediated endothelial ...

Objective Lupus nephritis (LN) is characterised by renal endothelial dysfunction, which contributes to progressive kidney injury. Endothelial nitric oxide synthase (eNOS) plays a modulating role in LN ...
lupus.bmj

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...
lupus.bmj

Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials

Objective The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary ...
lupus.bmj

Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study

Objectives We aimed to investigate which elementary lesions, identified through conventional brain MRI, correlated with the attribution of neuropsychiatric (NP) manifestations of SLE as determined by ...